NCT00734565View on ClinicalTrials.gov

Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Haemophilus Influenzae Type b
Interventions
BIOLOGICAL

Haemophilus influenzae type b

1 dose monovalent conjugated vaccine against Haemophilus influenzae type b in children aged 16 - 20 months and infants aged 2 - 4 months

Trial Locations (1)

050800

Vaccination site, Shijiazhuang

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY

NCT00734565 - Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b | Biotech Hunter | Biotech Hunter